Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

V-ATPases and osteoclasts: ambiguous future of V-ATPases inhibitors in osteoporosis.

Duan X, Yang S, Zhang L, Yang T.

Theranostics. 2018 Oct 26;8(19):5379-5399. doi: 10.7150/thno.28391. eCollection 2018. Review.

2.

V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.

Qin A, Cheng TS, Pavlos NJ, Lin Z, Dai KR, Zheng MH.

Int J Biochem Cell Biol. 2012 Sep;44(9):1422-35. doi: 10.1016/j.biocel.2012.05.014. Epub 2012 May 29. Review.

PMID:
22652318
3.

Disruption of the V-ATPase functionality as a way to uncouple bone formation and resorption - a novel target for treatment of osteoporosis.

Thudium CS, Jensen VK, Karsdal MA, Henriksen K.

Curr Protein Pept Sci. 2012 Mar;13(2):141-51. Review.

PMID:
22044152
4.

Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.

Xu J, Cheng T, Feng HT, Pavlos NJ, Zheng MH.

Histol Histopathol. 2007 Apr;22(4):443-54. doi: 10.14670/HH-22.443. Review.

PMID:
17290355
5.

The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis.

Yuan FL, Li X, Lu WG, Li CW, Li JP, Wang Y.

Mol Biol Rep. 2010 Oct;37(7):3561-6. doi: 10.1007/s11033-010-0004-7. Epub 2010 Feb 25. Review.

PMID:
20182803
6.

A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.

Nyman JK, Väänänen HK.

Calcif Tissue Int. 2010 Sep;87(3):273-83. doi: 10.1007/s00223-010-9395-7. Epub 2010 Jul 2.

PMID:
20596699
7.

Inhibition of osteoclast bone resorption by disrupting vacuolar H+-ATPase a3-B2 subunit interaction.

Kartner N, Yao Y, Li K, Crasto GJ, Datti A, Manolson MF.

J Biol Chem. 2010 Nov 26;285(48):37476-90. doi: 10.1074/jbc.M110.123281. Epub 2010 Sep 13.

8.

Inhibition of the osteoclast V-ATPase by small interfering RNAs.

Hu Y, Nyman J, Muhonen P, Väänänen HK, Laitala-Leinonen T.

FEBS Lett. 2005 Sep 12;579(22):4937-42.

9.

Iejimalides show anti-osteoclast activity via V-ATPase inhibition.

Kazami S, Muroi M, Kawatani M, Kubota T, Usui T, Kobayashi J, Osada H.

Biosci Biotechnol Biochem. 2006 Jun;70(6):1364-70.

10.

Murine ameloblasts are immunonegative for Tcirg1, the v-H-ATPase subunit essential for the osteoclast plasma proton pump.

Bronckers AL, Lyaruu DM, Bervoets TJ, Medina JF, DenBesten P, Richter J, Everts V.

Bone. 2012 Apr;50(4):901-8. doi: 10.1016/j.bone.2011.12.019. Epub 2012 Jan 8.

11.
12.

Selective inhibition of osteoclast vacuolar H(+)-ATPase.

Farina C, Gagliardi S.

Curr Pharm Des. 2002;8(23):2033-48. Review.

PMID:
12171517
13.

Luteolin inhibition of V-ATPase a3-d2 interaction decreases osteoclast resorptive activity.

Crasto GJ, Kartner N, Yao Y, Li K, Bullock L, Datti A, Manolson MF.

J Cell Biochem. 2013 Apr;114(4):929-41. doi: 10.1002/jcb.24434.

PMID:
23129004
14.

Effects of human a3 and a4 mutations that result in osteopetrosis and distal renal tubular acidosis on yeast V-ATPase expression and activity.

Ochotny N, Van Vliet A, Chan N, Yao Y, Morel M, Kartner N, von Schroeder HP, Heersche JN, Manolson MF.

J Biol Chem. 2006 Sep 8;281(36):26102-11. Epub 2006 Jul 13.

15.

Rational identification of enoxacin as a novel V-ATPase-directed osteoclast inhibitor.

Toro EJ, Ostrov DA, Wronski TJ, Holliday LS.

Curr Protein Pept Sci. 2012 Mar;13(2):180-91. Review.

16.

The R740S mutation in the V-ATPase a3 subunit results in osteoclast apoptosis and defective early-stage autophagy.

Ochotny N, Voronov I, Owen C, Aubin JE, Manolson MF.

J Cell Biochem. 2013 Dec;114(12):2823-33. doi: 10.1002/jcb.24630.

PMID:
23908015
17.

Diversity of proton pumps in osteoclasts: V-ATPase with a3 and d2 isoforms is a major form in osteoclasts.

Matsumoto N, Daido S, Sun-Wada GH, Wada Y, Futai M, Nakanishi-Matsui M.

Biochim Biophys Acta. 2014 Jun;1837(6):744-9. doi: 10.1016/j.bbabio.2014.02.011. Epub 2014 Feb 19.

18.
19.

Vacuolar H+-ATPase d2 subunit: molecular characterization, developmental regulation, and localization to specialized proton pumps in kidney and bone.

Smith AN, Jouret F, Bord S, Borthwick KJ, Al-Lamki RS, Wagner CA, Ireland DC, Cormier-Daire V, Frattini A, Villa A, Kornak U, Devuyst O, Karet FE.

J Am Soc Nephrol. 2005 May;16(5):1245-56. Epub 2005 Mar 30.

20.

Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.

Sørensen MG, Henriksen K, Neutzsky-Wulff AV, Dziegiel MH, Karsdal MA.

J Bone Miner Res. 2007 Oct;22(10):1640-8.

Supplemental Content

Support Center